In the latest analyst update, Roth Capital has initiated coverage on Insmed (INSM) with a "Buy" rating as of January 23, 2026. The analyst, Adam Walsh, has set a price target of $212.00 for the biotechnology company. This marks a significant development in the market's view of Insmed as the company continues to make strides in its field.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.